02:20 PM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) reported a phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%.

The stock plunged 65% with intraday volume topping 15.8 million shares versus a daily average of 134,000.

Genelux ( GNLX ) priced an underwritten public offering of 6.9 million shares and related warrants at a combined price of $4 a share for expected gross proceeds of $27.5 million.

Shares plummeted 41% as volume topped 2.99 million versus the daily average of about 139,000.

Workday (WDAY) shares slumped 15% after the company cut its full-year subscription sales outlook despite better-than-expected results in fiscal Q1.

Volume topped 11.1 million versus the daily average of 2.2 million.

Price: 4.21, Change: -7.97, Percent Change: -65.46